RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...
RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) presented new clinical and real-world data on its cardiovascular RNAi portfolio at the American College of Cardiology’s Annual Scientific Session. The company ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...
Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...
Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up ...
ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...
The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results